PHILADELPHIA, PA--(Marketwire - September 16, 2009) - Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that John Fraher, Chief Commercial Officer, is scheduled to present at the following conference:
Event: UBS Global Life Sciences Conference Date: Monday, September 21, 2009 Time: 1:30 p.m. ET Location: Grand Hyatt Hotel New York, N.Y.
An audio webcast of the Company’s presentation will be available by accessing the investor relations section of Eurand’s web site at www.eurand.com and will be available via replay.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. The Company’s technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.
Contacts:
Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
Email Contact
Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
Email Contact
Email Contact
